Gilead Sciences, Inc. $GILD Shares Sold by Seizert Capital Partners LLC

Seizert Capital Partners LLC reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,468 shares of the biopharmaceutical company’s stock after selling 7,791 shares during the period. Seizert Capital Partners LLC’s holdings in Gilead Sciences were worth $4,381,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GoalVest Advisory LLC boosted its stake in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at $26,000. Harbor Asset Planning Inc. bought a new position in Gilead Sciences during the second quarter valued at about $27,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter worth about $30,000. Finally, Putney Financial Group LLC raised its position in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 94 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research reports. Argus raised their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Wells Fargo & Company raised their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Needham & Company LLC lifted their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Finally, Citigroup boosted their target price on Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $133.28.

Gilead Sciences Price Performance

GILD opened at $123.57 on Tuesday. The firm has a market capitalization of $153.31 billion, a P/E ratio of 19.21, a PEG ratio of 0.66 and a beta of 0.33. The stock has a fifty day moving average of $123.49 and a 200-day moving average of $118.20. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12-month low of $91.84 and a 12-month high of $128.70.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is 48.99%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.10, for a total value of $356,515.50. Following the transaction, the director directly owned 1,339 shares of the company’s stock, valued at $170,186.90. This represents a 67.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the sale, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. This represents a 2.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 136,757 shares of company stock valued at $16,951,612 in the last quarter. Corporate insiders own 0.27% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.